Fluzoparib
Tier C — Watch / tradeFluzoparib
Targets：PARP1, PARP-2
Brand：AiRuiYi
Indications (approved)：Breast cancer, Peritoneal cancer, Ovarian cancer, Fallopian tube cancer
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| FLUZO-001 | 763114-26-7Available | 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid |
| FLUZO-002 | 681249-57-0 | 2-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine |
| Fluzoparib | 1358715-18-0 | - |
Frequently asked questions
What are the approved indications of Fluzoparib?
Approved indications include: Breast cancer, Peritoneal cancer, Ovarian cancer, Fallopian tube cancer.
When does the Fluzoparib patent expire?
No public expiry year is available for Fluzoparib yet; this page updates once verified.
How many synthesis routes are recorded for Fluzoparib?
1 synthesis routes are recorded; the shortest is 1 steps with 205 mg (Fluzoparib) total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Fluzoparib intermediates?
1 intermediate CAS of Fluzoparib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Fluzoparib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29